Skip to main content

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.

Publication ,  Journal Article
Wang, T; Nichols, HB; Nyante, SJ; Bradshaw, PT; Moorman, PG; Kabat, GC; Parada, H; Khankari, NK; Teitelbaum, SL; Terry, MB; Santella, RM ...
Published in: JNCI Cancer Spectr
June 2020

BACKGROUND: Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE1) and 16-hydroxyestrone (16-OHE1) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer. METHODS: This population-based study was initiated in 1996-1997 with spot urine samples obtained shortly after diagnosis (mean = 96 days) from 683 women newly diagnosed with first primary breast cancer and 434 age-matched women without breast cancer. We measured urinary concentrations of 2-OHE1 and 16-OHE1 using an enzyme-linked immunoassay. Vital status was determined via the National Death Index (n = 244 deaths after a median of 17.7 years of follow-up). We used multivariable-adjusted Cox proportional hazards to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the estrogen metabolites-mortality association. We evaluated effect modification using likelihood ratio tests. All statistical tests were two-sided. RESULTS: Urinary concentrations of the 2-OHE1 to 16-OHE1 ratio (>median of 1.8 vs ≤median) were inversely associated with all-cause mortality (HR = 0.74, 95% CI = 0.56 to 0.98) among women with breast cancer. Reduced hazard was also observed for breast cancer mortality (HR = 0.73, 95% CI = 0.45 to 1.17) and cardiovascular diseases mortality (HR = 0.76, 95% CI = 0.47 to 1.23), although the 95% confidence intervals included the null. Similar findings were also observed for women without breast cancer. The association with all-cause mortality was more pronounced among breast cancer participants who began chemotherapy before urine collection (n = 118, HR = 0.42, 95% CI = 0.22 to 0.81) than among those who had not (n = 559, HR = 0.98, 95% CI = 0.72 to 1.34; P interaction = .008). CONCLUSIONS: The urinary 2-OHE1 to 16-OHE1 ratio may be inversely associated with long-term all-cause mortality, which may depend on cancer treatment status at the time of urine collection.

Duke Scholars

Published In

JNCI Cancer Spectr

DOI

EISSN

2515-5091

Publication Date

June 2020

Volume

4

Issue

3

Start / End Page

pkaa014

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wang, T., Nichols, H. B., Nyante, S. J., Bradshaw, P. T., Moorman, P. G., Kabat, G. C., … Gammon, M. D. (2020). Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer. JNCI Cancer Spectr, 4(3), pkaa014. https://doi.org/10.1093/jncics/pkaa014
Wang, Tengteng, Hazel B. Nichols, Sarah J. Nyante, Patrick T. Bradshaw, Patricia G. Moorman, Geoffrey C. Kabat, Humberto Parada, et al. “Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.JNCI Cancer Spectr 4, no. 3 (June 2020): pkaa014. https://doi.org/10.1093/jncics/pkaa014.
Wang T, Nichols HB, Nyante SJ, Bradshaw PT, Moorman PG, Kabat GC, et al. Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer. JNCI Cancer Spectr. 2020 Jun;4(3):pkaa014.
Wang, Tengteng, et al. “Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer.JNCI Cancer Spectr, vol. 4, no. 3, June 2020, p. pkaa014. Pubmed, doi:10.1093/jncics/pkaa014.
Wang T, Nichols HB, Nyante SJ, Bradshaw PT, Moorman PG, Kabat GC, Parada H, Khankari NK, Teitelbaum SL, Terry MB, Santella RM, Neugut AI, Gammon MD. Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer. JNCI Cancer Spectr. 2020 Jun;4(3):pkaa014.

Published In

JNCI Cancer Spectr

DOI

EISSN

2515-5091

Publication Date

June 2020

Volume

4

Issue

3

Start / End Page

pkaa014

Location

England

Related Subject Headings

  • 3211 Oncology and carcinogenesis